Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - zuclopenthixol acetate - film-coated tablet - zuclopenthixol acetate 2 mg - psycholeptics

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - zuclopentixol - film-coated tablet - zuclopentixol 10 mg - psycholeptics

Canada - English - Health Canada

lundbeck canada inc - zuclopenthixol (zuclopenthixol hydrochloride) - tablet - 10mg - zuclopenthixol (zuclopenthixol hydrochloride) 10mg - thioxanthenes

Canada - English - Health Canada

lundbeck canada inc - zuclopenthixol (zuclopenthixol hydrochloride) - tablet - 25mg - zuclopenthixol (zuclopenthixol hydrochloride) 25mg - thioxanthenes

Canada - English - Health Canada

lundbeck canada inc - zuclopenthixol acetate - solution - 50mg - zuclopenthixol acetate 50mg - thioxanthenes

Canada - English - Health Canada

lundbeck canada inc - zuclopenthixol decanoate - solution - 200mg - zuclopenthixol decanoate 200mg - thioxanthenes

Australia - English - Department of Health (Therapeutic Goods Administration)

iotech pty ltd - sodium amidotrizoate, quantity: 3.705 g - oral liquid, solution - excipient ingredients: sorbitol; acesulfame potassium; quinoline yellow; methyl hydroxybenzoate; citric acid; purified water; flavour - ioscan is a contrast medium for computerised axial tomograpghy examination of the gastrointestinal tract. it should be made up with water prior to use, and administered orally. it is indicated primarily for use when barium sulphate is not appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - nevirapine hemihydrate, quantity: 10.35 mg/ml (equivalent: nevirapine, qty 10 mg/ml) - oral liquid, suspension - excipient ingredients: purified water; sorbitol solution (70 per cent) (non-crystallising); propyl hydroxybenzoate; sodium hydroxide; carbomer 934p; polysorbate 80; sucrose; methyl hydroxybenzoate - viramune (nevirapine) oral suspension in combination with antiretroviral agents is indicated for the treatment of hiv-1 infection in adults and children over the age of 2 months. viramune xr (nevirapine) extended-release tablets in combination with antiretroviral agents is indicated for the treatment of hiv-1 infection in adults and children over the age of three years. extended-release tablets are not suitable for the 14 day lead-in period for patients starting nevirapine. other nevirapine formulations, such as immediate-release tablets or oral suspension should be used. resistant virus emerges rapidly when viramune is administered as monotherapy or in dual combination therapy with an antiretroviral agent. therefore, viramune should always be administered in combination with at least two additional antiretroviral agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - riluzole, quantity: 0.5 g - oral liquid, suspension - excipient ingredients: sorbitol solution (70 per cent) (non-crystallising); aluminium magnesium silicate; xanthan gum; saccharin sodium; sodium lauryl sulfate; ceteareth-25; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; dimeticonol; peg-4 stearate; silicon dioxide - riluzole is indicated for the treatment of patients with amyotrophic lateral sclerosis (als).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - furosemide, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: glycerol; purified water; sodium hydroxide; sorbitol solution (70 per cent) (non-crystallising); methyl hydroxybenzoate; ethanol; propyl hydroxybenzoate; sunset yellow fcf; quinoline yellow; flavour - oedema: lasix is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. lasix is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. lasix injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset of diuresis is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, lasix is indicated by the intravenous route. parenteral use should be replaced with oral lasix as soon as practical.hypertension. oral lasix may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controll